

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: BIL1/19 - Bilirubin Neonatal

Dead line: 22.02.2019

| | | |
|--|--|--|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U _{AV} = expanded uncertainty of the assigned value (k = 2) | |

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | |
|--------------------------------|----------|---------------|-----|--------|------------------|------------------|--------------|-----------------|------------------|----|----|------------------|------------------|------------------|--|--|--|--|--|--|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | | | | | |
| (215) Bilirubin total | | | | | 143 | | | | | | | | | | | | | | | |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | | | | | | | |
| Sample A | | 83,0 | 5,0 | 6,1 | 143 | | | | | | | | | | | | | | | |
| (1) Abbott | | 84,2 | 2,1 | 2,5 | 18 | 0 | | | | | | | | | | | | | | |
| (58) Beckman Coulter (Olympus) | | 82,1 | 2,9 | 3,5 | 34 | 0 | | | | | | | | | | | | | | |
| (60) Roche | | 78,5 | 2,2 | 2,8 | 41 | 0 | | | | | | | | | | | | | | |
| (149) Siemens (Dade) | | 86,0 | 1,8 | 2,1 | 15 | 0 | | | | | | | | | | | | | | |
| (179) Siemens (Bayer) | | 89,2 | 3,4 | 3,8 | 23 | 0 | | | | | | | | | | | | | | |
| Other | | | | | 12 | 0 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 261 | 18 | 6,7 | 143 | | | | | | | | | | | | | | | |
| (1) Abbott | | 262 | 9,3 | 3,5 | 18 | 0 | | | | | | | | | | | | | | |
| (58) Beckman Coulter (Olympus) | | 254 | 7,2 | 2,8 | 34 | 0 | | | | | | | | | | | | | | |
| (60) Roche | | 248 | 8,7 | 3,5 | 41 | 0 | | | | | | | | | | | | | | |
| (149) Siemens (Dade) | | 273 | 7,0 | 2,5 | 15 | 0 | | | | | | | | | | | | | | |
| (179) Siemens (Bayer) | | 289 | 13 | 4,4 | 23 | 0 | | | | | | | | | | | | | | |
| Other | | | | | 12 | 0 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | |

1x 9, 4x 12, 1x 40, 1x 61, 1x 71, 2x 166, 1x 177, 1x 999

st_kn_np

End of report

Printed: 02.03.2019